EU Medicines Agency @EMA_News@respublicae.eu

RT @VTrillet_Lenoir: 💊Visite du siège @EMA_News à Amsterdam aujourd’hui.

👏🏻Merci aux équipes pour les fructueux échanges autour de la lutte contre les pénuries de médicaments, la résistance aux antibiotiques et les priorités de la future révision de la législation pharmaceutique européenne.

🐦🔗: https://n.respublicae.eu/EMA_News/status/1627955629540220929

The agenda of EMA's human medicines committee #CHMP is now published.
Find out what medicines will be discussed this month 💊💉
The committee highlights will be released on Friday.
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-23-26-february-2023_en.pdf

🐦🔗: https://n.respublicae.eu/EMA_News/status/1627646407543848960

It’s now easier to access information about medicines EMA publishes in different #EUlanguages. 💻

Our new Languages webpage provides links to translated content and explains what we translate and why, based on our new policy on #multilingualism.

🐦🔗: https://n.respublicae.eu/EMA_News/status/1627636191666348032

RT @HardemanHildeML: Very pleased we’re able to invite you to #ENDORSE2023! Join us to discuss the force and the potential of multilingual reference data and semantic technologies ... in the information we provide to the public and in our everyday lives.

Register soon! https://op.europa.eu/en/web/endorse?pk_campaign=ENDORSE2023_160223_HH_teaser_medium=tw

🐦🔗: https://n.respublicae.eu/EMA_News/status/1626554561111498756

Congratulations to our Executive Director, Emer Cooke, for this award!
RT @emireland: Today, we honour Emer Cooke as the European of the Year.

This is her story and the story of our prestigious award.

📽️: https://www.youtube.com/watch?v=l0UAXR1ywiM&feature=youtu.be

#EuropeanOfTheYear 🏆 | @EMA_News

🐦🔗: https://n.respublicae.eu/EMA_News/status/1626257906868920321

EMA recommended 8⃣9⃣ human #medicines for marketing authorisation in 2022.

4⃣1⃣ had a new active substance which had never been authorised in the 🇪🇺 before.

Consult our annual human medicines highlights: https://ema.europa.eu/en/news/human-medicines-highlights-2022

#PublicHealth #HealthUnion

🐦🔗: https://n.respublicae.eu/EMA_News/status/1626255686995742734

EMA recommended 1⃣0⃣ #VeterinaryMedicines for marketing authorisation in 2022. 🐈🐖🐎

3⃣ had a new active substance.

2⃣ were vaccines, including one new biotechnological vaccine.💉

Don’t miss our annual veterinary medicines highlights: https://www.ema.europa.eu/en/news/veterinary-medicines-highlights-2022

#OneHealth

🐦🔗: https://n.respublicae.eu/EMA_News/status/1626185674150871047

EMA recommended 8⃣9⃣ human #medicines for marketing authorisation in 2022.

4⃣0⃣ had a new active substance which had never been authorised in the 🇪🇺 before.

Consult our annual human medicines highlights: https://www.ema.europa.eu/en/news/human-medicines-highlights-2022

#PublicHealth #HealthUnion

🐦🔗: https://n.respublicae.eu/EMA_News/status/1626166931496570881

#RealWorldData on the #Mpox vaccine show that it is effective, especially after 2⃣ doses.

Discussions are ongoing with developers of other vaccines for Mpox and other viruses of the same type.

#EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845803758518273

❗️ #LongCovid is high on our agenda.

Current focus of many researchers is characterisation of the disease burden & clinical symptoms.

We are engaging with developers to discuss the design of clinical studies & what concrete measurable outcomes may look like.

#EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845560493178880

We are evaluating an #RSV vaccine for older adults with a possible recommendation in the next months.
There is a need to better protect vulnerable groups against respiratory viruses 🦠 that might cause disease waves in winter. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845192136720385

EMA is in contact with developers of mucosal #COVID19vaccines. We are ready to discuss emerging data from the vaccines that have already been deployed in India 🇮🇳 and China 🇨🇳. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844975073214472

We collaborate closely with @WHO to enable access to safe and effective vaccines in many countries around the 🌍. #UnitedInProtection #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844973110235138

The assessment of #COVID19Vaccine HIPRA 💉 is progressing, and we hope to conclude it very soon. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844808404049920

We are discussing with international partners criteria and the process for an update of the #COVID19Vaccines. 💉
Vaccination campaigns could take place primarily once a year and at the start of the winter❄️. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844608402849793

We encourage elderly people, pregnant persons and immunocompromised patients who have not been revaccinated against #COVID with an #AdaptedVaccine, to do so.
#UnitedInProtection #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625843660649598976

COVID-19 still poses a significant burden on healthcare systems. The low uptake of #booster doses among vulnerable groups is a concern for #PublicHealth. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625843339017830400